The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action
Open accessAbstract
Metformin is among the most widely prescribed drugs for the treatment of type 2 diabetes. Organic cation transporter 1 (OCT1) plays a role in the hepatic uptake of metformin, but its role in the therapeutic effects of the drug, which involve activation of AMP-activated protein kinase (AMPK), is unknown. Recent studies have shown that human OCT1 is highly polymorphic. We investigated whether OCT1 plays a role in the action of metformin and whether individuals with OCT1 polymorphisms have reduced response to the drug. In mouse hepatocytes, deletion of Oct1 resulted in a reduction in the effects of metformin on AMPK phosphorylation and gluconeogenesis. In Oct1-deficient mice the glucose-lowering effects of metformin were completely abolished. Seven nonsynonymous polymorphisms of OCT1 that exhibited reduced uptake of metformin were identified. Notably, OCT1-420del (allele frequency of about 20% in white Americans), previously shown to have normal activity for model substrates, had reduced activity for metformin. In clinical studies, the effects of metformin in glucose tolerance tests were significantly lower in individuals carrying reduced function polymorphisms of OCT1. Collectively, the data indicate that OCT1 is important for metformin therapeutic action and that genetic variation in OCT1 may contribute to variation in response to the drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 5×
“Downstream, metformin-stimulated AMPK phosphorylation results in a decrease in hepatic gluconeogenesis (4, 7).”
BackgroundMethodInfluentialThe Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
LKB1 is the upstream kinase in the AMP-activated protein kinase cascade
Woods, A., Johnstone, S. R., Dickerson, K., Leiper, F. C., Fryer, L. G. D., Neumann, D., Schlattner, U., Wallimann, T., Carlson, M., & Carling, D. (2003) · Current Biology · doi:10.1016/j.cub.2003.10.031 · Cited by 1,650
THE AMP-ACTIVATED/SNF1 PROTEIN KINASE SUBFAMILY: Metabolic Sensors of the Eukaryotic Cell?
Hardie, D. G., Carling, D., & Carlson, M. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.821 · Cited by 1,435
[4] Isolation and use of liver cells
(1978) · Methods in Enzymology · doi:10.1016/s0076-6879(78)52006-5 · Cited by 1,221
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084
Ram�rez-Zacar�as, J. L., Castro-Mu�ozledo, F., & Kuri-Harcuch, W. (1992) · Histochemistry · doi:10.1007/bf00316069 · Cited by 1,008
Metformin reverses fatty liver disease in obese, leptin-deficient mice.
Lin, H. Z., Yang, S. Q., Chuckaree, C., Kuhajda, F., Ronnet, G., & Diehl, A. M. (2000) · Nature Medicine · doi:10.1038/79697 · Cited by 673
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin
Wang, D.-S., Jonker, J. W., Kato, Y., Kusuhara, H., Schinkel, A. H., & Sugiyama, Y. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034140 · Cited by 441
Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity
Zhang, S., Lovejoy, K. S., Shima, J. E., Lagpacan, L. L., Shu, Y., Lapuk, A., Chen, Y., Komori, T., Gray, J. W., Chen, X., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0769 · Cited by 431
Self-citationCloning and Functional Expression of a Human Liver Organic Cation Transporter
Zhang, L., Dresser, M. J., Gray, A. T., Yost, S. C., Terashita, S., & Giacomini, K. M. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.6.913 · Cited by 417
Self-citationMetformin is a Superior Substrate for Renal Organic Cation Transporter OCT2 rather than Hepatic OCT1
Kimura, N., Masuda, S., Tanihara, Y., Ueo, H., Okuda, M., Katsura, T., & Inui, K.-I. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.379 · Cited by 360
Hermann, L. S., Scherstén, B., Bitzén, P.-O., Kjellström, T., Lindgärde, F., & Melander, A. (1994) · Diabetes Care · doi:10.2337/diacare.17.10.1100 · Cited by 344
Dresser, M. J., Leabman, M. K., & Giacomini, K. M. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200104)90:4<397::aid-jps1000>3.0.co;2-d · Cited by 290
Self-citationShu, Y., Leabman, M. K., Feng, B., Mangravite, L. M., Huang, C. C., Stryke, D., Kawamoto, M., Johns, S. J., DeYoung, J., Carlson, E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730858100 · Cited by 285
Self-citationJonker, J. W., Wagenaar, E., Mol, C. A. A. M., Buitelaar, M., Koepsell, H., Smit, J. W., & Schinkel, A. H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.16.5471-5477.2001 · Cited by 227
Leabman, M. K., Huang, C. C., DeYoung, J., Carlson, E. J., Taylor, T. R., de la Cruz, M., Johns, S. J., Stryke, D., Kawamoto, M., Urban, T. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730857100 · Cited by 220
Self-citationKerb, R., Brinkmann, U., Chatskaia, N., Gorbunov, D., Gorboulev, V., Mornhinweg, E., Keil, A., Eichelbaum, M., & Koepsell, H. (2002) · Pharmacogenetics · doi:10.1097/00008571-200211000-00002 · Cited by 214
The Effects of AICAR on Adipocyte Differentiation of 3T3-L1 Cells
Habinowski, S. A., & Witters, L. A. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5484 · Cited by 211
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function
Leabman, M. K., Huang, C. C., Kawamoto, M., Johns, S. J., Stryke, D., Ferrin, T. E., DeYoung, J., Taylor, T., Clark, A. G., Herskowitz, I., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200207000-00007 · Cited by 191
Self-citationInvolvement of Organic Cation Transporter 1 in the Lactic Acidosis Caused by Metformin
Wang, D.-S., Kusuhara, H., Kato, Y., Jonker, J. W., Schinkel, A. H., & Sugiyama, Y. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.4.844 · Cited by 191
Abbud, W., Habinowski, S., Zhang, J.-Z., Kendrew, J., Elkairi, F. S., Kemp, B. E., Witters, L. A., & Ismail-Beigi, F. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.1935 · Cited by 183
Guigas, B., Bertrand, L., Taleux, N., Foretz, M., Wiernsperger, N., Vertommen, D., Andreelli, F., Viollet, B., & Hue, L. (2006) · Diabetes · doi:10.2337/diabetes.55.04.06.db05-1178 · Cited by 180
Metformin: a review of its pharmacological properties and therapeutic use.
Ls, H. (1979) · PubMed · Cited by 173
Insulin Sensitizers for Polycystic Ovary Syndrome
Baillargeon, J., Iuorno, M. J., & Nestler, J. E. (2003) · Clinical Obstetrics & Gynecology · doi:10.1097/00003081-200306000-00011 · Cited by 148
Sakata, T., Anzai, N., Shin, H. J., Noshiro, R., Hirata, T., Yokoyama, H., Kanai, Y., & Endou, H. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.175 · Cited by 106
Caspary, W. F., & Creutzfeldt, W. (1971) · Diabetologia · doi:10.1007/bf01219474 · Cited by 98
Dresser, M. J., Xiao, G., Leabman, M. K., Gray, A. T., & Giacomini, K. M. (2002) · Pharmaceutical Research · doi:10.1023/a:1019870831174 · Cited by 92
Self-citationHermann, L. S., Scherstén, B., & Melander, A. (1994) · Diabetic Medicine · doi:10.1111/j.1464-5491.1994.tb00253.x · Cited by 86
Huypens, P., Quartier, E., PIPELEERS, D. G., & de Casteele, M. V. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.06.016 · Cited by 85
Enhanced glucose transport in response to inhibition of respiration in Clone 9 cells
Mercado, C. L., Loeb, J. N., & Ismail‐Beigi, F. (1989) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1989.257.1.c19 · Cited by 65
Estimating the contribution of genes and environment to variation in renal drug clearance
Leabman, M. K., & Giacomini, K. M. (2003) · Pharmacogenetics · doi:10.1097/00008571-200309000-00007 · Cited by 62
Self-citationRegulation of glucose transport by the AMP-activated protein kinase
FUJII, N. L., Aschenbach, W. G., Musi, N., Hirshman, M. F., & Goodyear, L. J. (2004) · Proceedings of The Nutrition Society · doi:10.1079/pns2004340 · Cited by 59
Functional genomics of membrane transporters in human populationsPreprint
Urban, T. J., Sebro, R., Hurowitz, E. H., Leabman, M. K., Badagnani, I., Lagpacan, L. L., RISCH, N. J., & Giacomini, K. M. (2005) · Genome Research · doi:10.1101/gr.4356206 · Cited by 54
Self-citation
Cited by
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Self-citationThe mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943
“Similarly, genetic polymorphisms in the cell surface transporter organic cation transporter 1 ( OCT1 ), which is required for efficient metformin uptake in hepatocytes, have been shown to underlie metformin resistance in some patients with type 2 diabete”
BackgroundCellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Steinberg, G. R., & Kemp, B. E. (2009) · Physiological Reviews · doi:10.1152/physrev.00011.2008 · Cited by 1,637
Metadata
- Authors
- Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., Ianculescu, A. G., Yue, L., Lo, J. C., Burchard, E. G., Brett, C. M., & Giacomini, K. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-05-01
- Volume
- 117
- Issue
- 5
- Pages
- 1422-1431
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1997003352
- Cited by
- 967
- References
- 34
- FWCI
- 43.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.